The FunGeST team at the Cordeliers Research Centre is proud to share that our group leader, Professor Jessica Zucman-Rossi, has been honoured with the 2025 EASL Recognition Award at the annual congress of the European Association for the Study of the Liver (EASL), a leading international event in hepatology.

This prestigious award recognises both the excellence of her scientific contributions and her strong commitment to collaborative, inclusive, and open research.

What I love most in research is the joy of collective discovery. Sometimes, something clicks, and this is a piece of the puzzle that falls into place that makes our understanding grow. When you begin to experience this, you are completely addicted to research. This type of discovery would not be possible without my team.

Warm congratulations to Professor Jessica Zucman-Rossi on this inspiring recognition, which resonates deeply with the entire Cordeliers Research Centre community!

Revealing HPV Insight Using Capture HPV and ViroCapt2 Analysis Within Immuneboost-HPV Cohort (NCT03838263)

ABSTRACT

Background. Hepatoblastoma is the most frequent pediatric liver cancer. The current treatments lead to 80% of survival rate at 5 years. In this study, we evaluated the clinical relevance of molecular features to identify patients at risk of chemoresistance, relapse and death of disease.
Methods. All the clinical data of 86 children with hepatoblastoma were retrospectively collected. Pathological slides were reviewed, tumor DNA sequencing (by whole exome, whole genome or target) and transcriptomic profiling with RNAseq or 300-genes panel were performed. Associations between the clinical, pathological, mutational and transcriptomic data were investigated.
Results. High-risk patients represented 44% of our series and the median age at diagnosis was 21.9 months (range: 0–208). Alterations of the WNT/ß-catenin pathway and of the 11p15.5 imprinted locus were identified in 98% and 74% of the tumors, respectively. Other cancer driver genes mutations were only found in less than 11% of tumors. After neoadjuvant chemotherapy, disease-specific survival and poor response to neoadjuvant chemotherapy were associated with ‘Liver Progenitor’ (p = 0.00049, p < 0.0001) and ‘Immune Cold’ (p = 0.0011, p < 0.0001) transcriptomic tumor subtypes, SBS35 cisplatin mutational signature (p = 0.018, p = 0.001), mutations in rare cancer driver genes (p = 0.0039, p = 0.0017) and embryonal predominant histological type (p = 0.0013, p = 0.0077), respectively. Integration of the clinical and molecular features revealed a cluster of molecular markers associated with resistance to chemotherapy and survival, enlightening transcriptomic ‘Immune Cold’ and Liver Progenitor’ as a predictor of survival independent of the clinical features.
Conclusions. Response to neoadjuvant chemotherapy and survival in children treated for hepatoblastoma are associated with genomic and pathological features independently of the clinical features.

Eric Letouzé and Stefano Caruso from our lab will present their works tomorrow at the CRC Scientific Day!

Don’t miss this day with high level science from our Research Center !

More informations on CRC website:

http://www.crc.jussieu.fr/journee_scientifique_du_crc.html

The Faculty of Medicine and Dentistry of UC Louvain will present the honoris causa doctor insignia today, May 29 2019 to our Director, Pr. Jessica Zucman-Rossi. A new prestigious reward for our director.

A French geneticist, Professor Jessica Zucman-Rossi holds a doctorate in medicine, a doctorate in life sciences from the University of Paris 7, and a specialization in internal medicine from the Paris Hospitals. She is the Director of the Cordeliers Research Centre and Professor of Medicine at the University of Paris Descartes.
His research work has enabled him to identify and understand the many genetic abnormalities that lead to the formation of benign and malignant liver tumours, and thus to optimize therapeutic follow-up of patients. His discoveries open the way to new personalized treatments based on knowledge of the tumor genome.

5pm30: Ceremony to present the insignia of Doctor honoris causa de l’Uclouvain to Professor Jessica Zucman-Rossi
6pm: lecture by Prof. Zucman-Rossi on the theme: “The natural history of liver tumours revisited by genomics”.

Don’t miss Nicolas A. Giraldo (John Hopkins, USA) talk tomorrow in Paris. He’s a former post Dc from the CRC. It’s free and it will be an excellent talk.

Tumor immunoprofiling: Novel tissue-based biomarkers in precision oncology

https://www.linkedin.com/feed/update/urn:li:activity:6499232342803124224